SecBot SecBot
SECBOTREPLAY Home › Report › OCUL

OCUL · Five senior executives at Ocular Therapeutix, including the Chief…

OCULAR THERAPEUTIX, INC · CLUSTER filed Sep 2, 2026 at 16:01 ET

At the news

NEUTRALIMPACT 4/10

CLUSTER filed Sep 2, 2026 at 16:01 ET

Five senior executives at Ocular Therapeutix, including the Chief Scientific Officer, Chief Operating Officer, and Chief Development Officer, sold a total of ~$333K in shares over a one-week period. While the dollar amount is modest relative to the $2.4B market cap (0.01%), the cluster involves multiple C-suite insiders selling on the same day, which warrants attention despite the academic literature showing cluster sales are less informative than buys. The sales follow a strong recent stock performance and occur ahead of potential pipeline catalysts for the company's lead drug candidate.

  • Five insiders sold shares totaling ~$333K from Aug 24-31, 2026
  • Sales include CSO, COO, Chief Development Officer, Chief Strategy Officer, and a senior executive
  • All sales were open-market transactions at prices between $10.24-$10.78
  • Total sales represent ~0.01% of OCUL's $2.4B market cap

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access